CN110914275A - 化合物、组合物及方法 - Google Patents

化合物、组合物及方法 Download PDF

Info

Publication number
CN110914275A
CN110914275A CN201880047315.8A CN201880047315A CN110914275A CN 110914275 A CN110914275 A CN 110914275A CN 201880047315 A CN201880047315 A CN 201880047315A CN 110914275 A CN110914275 A CN 110914275A
Authority
CN
China
Prior art keywords
optionally substituted
heterocyclyl
compound
disease
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880047315.8A
Other languages
English (en)
Chinese (zh)
Inventor
G·博纳诺米
A·A·埃斯特拉达
J·A·冯
B·福克斯
C·M·弗朗西尼
C·胡
C·P·莱斯利
M·奥西波夫
A·苏达卡尔
Z·K·斯威尼
J·德·维森特·菲达尔戈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CN110914275A publication Critical patent/CN110914275A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880047315.8A 2017-05-17 2018-05-17 化合物、组合物及方法 Pending CN110914275A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762507682P 2017-05-17 2017-05-17
US62/507,682 2017-05-17
PCT/US2018/033269 WO2018213634A1 (en) 2017-05-17 2018-05-17 Compounds, compositions and methods

Publications (1)

Publication Number Publication Date
CN110914275A true CN110914275A (zh) 2020-03-24

Family

ID=64274734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880047315.8A Pending CN110914275A (zh) 2017-05-17 2018-05-17 化合物、组合物及方法

Country Status (11)

Country Link
US (2) US11174262B2 (https=)
EP (1) EP3625234B1 (https=)
JP (2) JP7140781B2 (https=)
KR (1) KR102637541B1 (https=)
CN (1) CN110914275A (https=)
AU (2) AU2018269745C1 (https=)
BR (1) BR112019023979A2 (https=)
CA (1) CA3063938A1 (https=)
IL (1) IL270505B2 (https=)
MX (1) MX2019013642A (https=)
WO (1) WO2018213634A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025045281A3 (zh) * 2023-08-31 2025-04-24 杭州百诚医药科技股份有限公司 苯并氮杂䓬酮类化合物及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220636T1 (hr) 2016-12-09 2022-07-22 Denali Therapeutics Inc. Spojevi korisni kao inhibitori ripk1
CA3063938A1 (en) * 2017-05-17 2018-11-22 Denali Therapeutics Inc. Compounds, compositions and methods
CA3121920A1 (en) 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2023540223A (ja) * 2020-08-26 2023-09-22 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
EP4422621A4 (en) * 2021-10-27 2025-08-27 Merck Sharp & Dohme Llc SPIROTRICYCLIC RIPK1 INHIBITORS AND METHODS OF USE THEREOF

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4290952A (en) * 1980-06-23 1981-09-22 American Home Products Corporation Aryl-1-mercaptoalkanoylproline and homoproline derivatives
US20100190688A1 (en) * 2004-07-12 2010-07-29 Bin Chao Tetrapeptide analogs
US20110305777A1 (en) * 2006-07-24 2011-12-15 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
WO2016094846A1 (en) * 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
WO2016101887A1 (en) * 2014-12-24 2016-06-30 National Institute Of Biological Sciences, Beijing Necrosis inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4320057A (en) * 1980-06-23 1982-03-16 American Home Products Corporation Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
US7932382B2 (en) * 2004-01-16 2011-04-26 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
JP2008545780A (ja) * 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
JP6465803B2 (ja) * 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CA3063938A1 (en) * 2017-05-17 2018-11-22 Denali Therapeutics Inc. Compounds, compositions and methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4290952A (en) * 1980-06-23 1981-09-22 American Home Products Corporation Aryl-1-mercaptoalkanoylproline and homoproline derivatives
US20100190688A1 (en) * 2004-07-12 2010-07-29 Bin Chao Tetrapeptide analogs
US20110305777A1 (en) * 2006-07-24 2011-12-15 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
WO2016094846A1 (en) * 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
WO2016101887A1 (en) * 2014-12-24 2016-06-30 National Institute Of Biological Sciences, Beijing Necrosis inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PUBCHEM: "CID73441084-CID73441088", 《DATABASE 》 *
SB BERGER等: "Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase", 《CELL DEATH DISCOVERY》 *
YAN REN等: "Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome", 《J. MED. CHEM.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025045281A3 (zh) * 2023-08-31 2025-04-24 杭州百诚医药科技股份有限公司 苯并氮杂䓬酮类化合物及其用途

Also Published As

Publication number Publication date
JP7140781B2 (ja) 2022-09-21
EP3625234A1 (en) 2020-03-25
MX2019013642A (es) 2020-07-20
US20220024938A1 (en) 2022-01-27
CA3063938A1 (en) 2018-11-22
EP3625234A4 (en) 2021-03-10
IL270505A (https=) 2019-12-31
US11174262B2 (en) 2021-11-16
AU2018269745C1 (en) 2022-06-09
AU2022202524A1 (en) 2022-05-12
WO2018213634A1 (en) 2018-11-22
KR20200006120A (ko) 2020-01-17
BR112019023979A2 (pt) 2020-06-09
KR102637541B1 (ko) 2024-02-15
US20200079784A1 (en) 2020-03-12
JP2022174180A (ja) 2022-11-22
AU2022202524B2 (en) 2023-10-05
US11851433B2 (en) 2023-12-26
IL270505B2 (en) 2023-09-01
JP2020520925A (ja) 2020-07-16
AU2018269745B2 (en) 2022-01-27
IL270505B1 (en) 2023-05-01
EP3625234B1 (en) 2023-09-20
AU2018269745A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
US10709692B2 (en) Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
EP3676297B1 (en) Compounds, compositions and methods
KR102637541B1 (ko) 화합물, 조성물 및 방법
CN110913858B (zh) 激酶抑制剂及其用途
CN110383066B (zh) 化合物、组合物和方法
RU2720203C1 (ru) 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl
JP2020530446A (ja) 化合物、組成物、及び、方法
JP2022520236A (ja) 化合物、組成物、及び、方法
HK40016450B (en) Compounds useful as ripk1 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination